Arcus Biosciences (RCUS) Stock Price
$8.47 0%
to add to portfolio
AI Score
-
Alternative
6 -
Fundamental
2 -
Technical
3
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Arcus Biosciences, AI stock picks, stock alerts and much more.
RCUS AI Stock Analysis
AI stock analysis for RCUS is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Arcus Biosciences (RCUS) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Arcus Biosciences (RCUS) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Arcus Biosciences (RCUS), currently trading at $8.47, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About RCUS
-
Arcus Biosciences, Inc.
-
Symbol
RCUS
-
Market
NYSE
-
Industry
Biotechnology
-
Market Cap
896.8M
Similar Stocks
 |
Novo Nordisk NVO |
$69.17 0.9% |
6 |
 |
Zymeworks ZYME |
$13.04 1.2% |
5 |
 |
Ginkgo Bioworks Holdings DNA |
$12.72 0.5% |
3 |
News
RCUS Alternative Data
Web Traffic
Arcus Biosciences receives an estimated 15939 monthly visitors to arcusbio.com.
-
Web Traffic
15939
-
Change from Previous Month
32%
-
3 Month Change
65.6%
-
YoY Change
65.6%
Twitter Followers
Arcus Biosciences has 514 Twitter Followers on its main Twitter (also known as X) account, which is down by -22.1% over the last month.
-
Twitter Followers
514
-
Daily Change
0%
-
1 Month Change
22.1%
-
3 Month Change
24.6%
-
YoY Change
24.6%
Facebook Engagement
Arcus Biosciences has engaged 0 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
0
-
Daily Change
0%
-
1 Month Change
100%
-
3 Month Change
100%
-
YoY Change
100%
Instagram Followers
Arcus Biosciences has 86 Instagram Followers on its main Instagram account, up by 3.6% over the last month.
-
Instagram Followers
86
-
Daily Change
0%
-
1 Month Change
3.6%
-
3 Month Change
19.4%
-
YoY Change
19.4%
LinkedIn Followers
28,869 are following Arcus Biosciences on LinkedIn, up by 2.2% over the last month.
-
LinkedIn Followers
28869
-
Daily Change
0%
-
1 Month Change
2.2%
-
3 Month Change
6.7%
Job Postings
Arcus Biosciences has an estimated 13 open job postings, which is down -27.8% over the last month.
-
Job Postings
13
-
Daily Change
0%
-
1 Month Change
27.8%
-
3 Month Change
45.8%
-
YoY Change
45.8%
LinkedIn Employees
According to LinkedIn, Arcus Biosciences has 687 employees.
-
LinkedIn Employees
687
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
2.8%
-
YoY Change
2.8%
Reddit Mentions
Arcus Biosciences has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Business Outlook
According to employee reviews, the business outlook among employees at Arcus Biosciences is 54 out of 100 (neutral).
-
Business Outlook
54
-
Change from Previous Month
0%
-
3 Month Change
11.5%
-
YoY Change
11.5%
News Mentions
Arcus Biosciences was mentioned 1 times in the news yesterday.
-
News Mentions
1
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
RCUS Financials
RCUS Key Metrics
-
Total Revenue
$26M
-
Net Income
-$94M
-
Earnings per Share
-$1.04
-
Free cash flow
-$101M
-
EBITDA
-$89M
-
EBITDA Ratio
-3.42308
-
Total Assets
$1.2B
RCUS 2-year Revenue & Income
RCUS 2-year Free Cash Flow
RCUS Technicals
RCUS SMA
RCUS RSI
FAQ
What's the current price of Arcus Biosciences (RCUS) Stock?
The price of an Arcus Biosciences (RCUS) share is $8.47.
What's the market cap of Arcus Biosciences?
The current market cap of Arcus Biosciences is 896.8M.
Should I buy or sell RCUS?
Arcus Biosciences shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Arcus Biosciences is better viewed as a hold or accumulate position while waiting for further developments.
Is Arcus Biosciences a good investment?
The current analysis of Arcus Biosciences' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Arcus Biosciences' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Arcus Biosciences (RCUS) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Arcus Biosciences stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Arcus Biosciences (RCUS) that investors often compare it to?
Arcus Biosciences (RCUS) is often compared to similar stocks such as Novo Nordisk, Zymeworks and Ginkgo Bioworks Holdings.
What is the forecast for Arcus Biosciences' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Arcus Biosciences' stock price to be around $8.37 in 2026. Starting from the current price of $8.47, this represents a 1.2% change in price, indicating a neutral outlook for the stock.
How to buy Arcus Biosciences (RCUS) Stock?
Arcus Biosciences stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Arcus Biosciences shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.